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Background: p53 is the most frequently mutated tumor-suppressor gene in human cancers. It has been reported
that mutations in p53 result not only in the loss of its ability as a tumor suppressor, but also in the gain of novel
cancer-related functions that contribute to oncogenesis. The present study evaluated the potential of silencing of
mutant p53 by small interfering RNA in the treatment of bladder cancer cells in vitro.
Methods: We used the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay to assess cell
viability and flow cytometry to detect cell cycle alterations and apoptosis. The related molecular mechanisms were
assessed by western blotting. We also used the MTT assay and flow cytometry to investigate if silencing of mutant
p53 by knockdown with small interfering (si)RNA would change the sensitivity to cisplatin treatment.
Results: Using 5637 and T24 human bladder cancer cell lines characterized by mutations in p53, we found that
silencing of the mutant p53 by RNA interference induced evident inhibition of cell proliferation and viability, which
was related to the induction of G2 phase cell cycle arrest and apoptosis. Moreover, our study also showed that the
p53-targeting siRNA cooperated with cisplatin in the inhibition of bladder cancer cells.
Conclusions: These findings suggest that RNA interference targeting mutant p53 may be a promising therapeutic
strategy for the treatment of bladder cancer.
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Bladder cancer is the fourth most common cancer in
men, with an estimated 73,510 new cases of and 14,880
deaths from bladder cancer in the USA In 2012 [1].
Although chemotherapy has revolutionized the treatment
of advanced tumors [2,3], cisplatin-containing combi-
nation chemotherapy for metastatic disease achieves only
a median survival of up to 14 months [4], and the asso-
ciated side-effects induced by its lack of specificity for
tumor cells remain a challenging problem. Therefore,
novel therapeutic strategies for the treatment of advanced
bladder cancer are urgently required.* Correspondence: lpxie@yahoo.cn
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reproduction in any medium, provided the orThe well-known tumor suppressor p53 (encoded by the
human gene TP53), which functions primarily as a tran-
scription factor, plays a vital role in protecting cells from a
variety of cellular stresses, including DNA damage and
oncogene activation. These stresses trigger the accumula-
tion of p53 protein and activate its transcriptional activity,
which prevents cell transformation by inducing cell cycle
arrest, senescence, apoptosis, DNA repair, or autophagy
[5,6]. TP53 mutations occur in approximately half of all
human cancers, and the majority abrogates the sequence-
specific DNA-binding activity of the p53 protein, which
constitutes a corner-stone in tumorigenesis [7-9]. More-
over, these mutations usually exert cancer-promoting
effects, not only by dominant-negative inactivation of the
remaining wild-type allele [10,11], but also through
authentic oncogenic gain-of-function activities, which in-
clude a wide range of newly acquired oncogenic properties
that are not found in the wild-type p53, such as increased. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sion and metastasis, and drug resistance and inhibition of
apoptosis [12], underlying the evidence for the association
of TP53 mutations with poor clinical outcome in a variety
of cancer types. In support of the gain-of-function hypoth-
esis, stable or conditional knockdown of endogenous p53
mutants in various human cancer cell lines were shown to
reduce their proliferation rate and chemoresistance in vitro,
and their ability to form tumors in nude mice [13,14].
Alterations in the p53 gene and its pathways are usually
implicated in muscle-invasive bladder cancer (T2-T4) and
advanced stages, and are associated with augmented
angiogenesis, invasiveness, metastasis, recurrence, and
consequent poor prognosis [15,16]. However, there have
been conflicting findings on whether p53 mutations confer
increased responsiveness or resistance to cisplatin-based
systemic chemotherapy in bladder cancer [17]. In this
study, we chose as models two bladder cancer cell lines,
T24 and 5637, which both have p53 mutations. The T24
cell line was found to contain a p53 mutation with an in-
frame deletion of tyrosine 126 [18], while the 5637 cells
carried the p53R280T mutant [19]. Our study showed that
knockdown of these p53 mutants by small interfering (si)
RNA not only induced cell cycle arrest and cell apoptosis
in T24 and 5637 bladder cancer cell lines, but also coop-
erated with cisplatin in the inhibition of these cancer cells,
suggesting that siRNAs may serve as alternative agents for
the treatment of bladder cancer by targeting mutant p53.
Methods
Reagents
The p53-targeting siRNA used was siP53 (Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA). The control
double-stranded small RNA siCon (Table 1) was designed
to lack significant homology to all known human sequences
and chemically synthesized (GeneChem; Shanghai, China).
We used primary immunoblotting antibodies against β-
actin, phospho-cyclin-dependent kinase (CDK)1, phospho-
CDK2, cyclin A, cyclin B1, cyclin D1, and cyclin E (Cell
Signaling Technologies, Beverly, MA, USA), and antibodies
against poly(ADP-ribose) polymerase (PARP), CDK1,
CDK2, CDK4, caspase-3, caspase-9, and p53 (Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA). This study has
been approved by the ethics committee of ZhejiangTable 1 Sequences of RNA and primers used in this study






Reverse GGAAGATGGTGATGGGATTTUniversity and performed according to our institutional
guidelines.
Cell culture and transfection
The human bladder cancer cell lines 5637 and T24
(Shanghai Institute of Cell Biology, Chinese Academy of
Science, Shanghai, China) were cultured in RPMI 1640
medium supplemented with 10% heat-inactivated fetal bo-
vine serum, 100 U/ml penicillin, and 100 mg/l streptomycin
in a humidified atmosphere containing 5% CO2 maintained
at 37°C. The day before transfection, cells were plated in
growth medium without antibiotics at a density of 30–40%.
Transfections of double-stranded (ds)RNA were carried out
using transfection reagent (Lipofectamine 2000; Invitrogen,
Carlsbad, CA, USA), in accordance with the manufacturer’s
protocol. Mock groups were treated with the transfection
reagent only. All cell groups were incubated for 24 or 48
hours. Cell images were taken using a phase-contrast
microscope at ×100 magnification (Olympus, Japan).
Real-time quantitative PCR
Total RNA was extracted (TRIzol reagent; Invitrogen,
Carlsbad, CA, USA) from the three groups of cells trans-
fected for 48 hours (mock group, 50 nmol/l siCon, and
50 nmol/l siP53) and reverse transcribed using oligo(dT)
primers and Moloney murine leukemia virus (M-MLV)
reverse transcriptase (Promega, Madison, WI, USA).
The resulting cDNA was amplified in a real-time PCR
system (ABI Prism 7500; Applied Biosystems, CA, USA)
using a commercial reagent (SYBR Premix Ex Taq™
Takara, Dalian, China). Values are expressed as fold dif-
ference compared with the mock group. Primer sequences
for p53 and GADPH are shown in Table 1.
Western blotting analysis
Briefly, cells were harvested at 48 hours after dsRNA
treatment as described above, washed, and lysed with
lysis buffer. Protein concentration in the resulting lysate
was determined using the bicinchoninic acid protein
assay kit (Pierce Biotechnology Inc., Rockford, IL, USA).
Appropriate amounts of protein (30–50 μg) were
resolved by electrophoresis in 8 to 12% Tris-glycine
polyacrylamide gels and transferred to nitrocellulose
membranes. Membranes were blocked and then incu-
bated overnight with the appropriate primary antibody
at dilutions specified by the manufacturer. They were
next washed three times in 15 ml Tris-buffered saline
with Triton (TBS-T) and incubated with the correspond-
ing horseradish peroxidase (HRP)-conjugated secondary
antibody at 1:1000 dilution in TBS-T for 1 hour. The
membranes were washed three times for 5 minutes each
with 15 ml TBS-T, then the bound secondary antibody
was detected using an enhanced chemiluminescence
(ECL) system (Pierce Biotechnology Inc.).
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Proliferation of cells was determined by the (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay. Approximately 3000 to 8000 (depending
on how long they would be cultured) cells were plated
in each well of a 96-well plate. After overnight incuba-
tion, the cells were treated with the appropriate dsRNA
(mock, 50 nmol/l siCon, or 5–100 nmol/l siP53) for 24,
48, or 72 hours, or with the dsRNA (50 nmol/l siCon or
siP53) for 24 hours, followed by incubation for 48 hours
with or without 1 μg/ml cisplatin. At the various times
after treatment, the medium was removed and MTT (20 μl
of a 5 mg/ml solution) was added to each well, and plates
were incubated at 37°C for 4 hours. After that, the plates
were spun in a centrifuge, and the purple-colored forma-
zan precipitate in each well was dissolved in 150 μl of
dimethyl sulfoxide. Absorbance was measured at 490 nm
in an absorbance reader (MRX II ; DYNEX Technologies,
Chantilly, VA, USA). The reduction in viability of each
group was expressed as a percentage of the mock or siCon
cells, which were considered to be 100% viable.
Cell cycle analysis by flow cytometry
Cell cycle analysis was performed using a commercial kit
(Coulter DNA Prep™ Reagents Kit; Beckman Coulter, Full-
erton, CA, USA). Cells were plated in six-well plates and
incubated overnight before treatment (mock, 50 nmol/l
siCon and 50 nmol/l siP53 for 48 hours or 50 nmol/l
siCon/siP53 for 24 hours with cisplatin or not for 48
hours-). Following treatment, cells were harvested, then
washed twice with pre-chilled PBS and resuspended in 100
μl PBS at a concentration of 1×106 cells/ml. Each cell sam-
ple was mixed with 100 μl DNA Prep LPR (contained in
Coulter DNA Prep™ Reagents Kit), gently mixed by vortex
and incubated in the dark at room temperature (25°C) for
20 minutes. Then each was mixed with 1 ml of stain (DNA
Prep Stain; contained in Coulter DNA Prep™ Reagents
Kit), gently mixed by vortex and again incubated in the
dark at room temperature (25°C) for 20 minutes. Finally,
cell cycle analysis was performed within 1 hour using flow
cytometry (Beckman Coulter FC500 Flow Cytometry
System with CXP Software; Beckman Coulter, Fullerton,
CA, USA), and the raw data was analyzed by Multicycle
for Windows (Beckman Coulter).
Detection of apoptotic cells by flow cytometry
A quantitative assessment of apoptosis was made by de-
termining the percentage of cells with highly condensed
or fragmented nuclei. Cells were harvested at 48 hours
after dsRNA treatment (mock, 50 nmol/l siCon, or 50
nmol/l siP53) as described above, washed twice
with pre-chilled PBS, and resuspended in 100 μl 1 ×
binding buffer at a concentration of 1 × 106 cells/ml.
Double staining with fluorescein isothiscyanate (FITC)-conjugated annexin V and propidium iodide (PI) was
performed (Annexin V-FITC Apoptosis Detection Kit;
BD Biosciences, San Jose, CA, USA) in accordance with
the manufacturer’s protocol. Cell apoptosis analysis was
performed within 1 hour by flow cytometry as described
above.
Statistical analysis
All values are expressed as means ± SD. Statistical sig-
nificance was compared between treatment groups and
controls using Student’s t test. P < 0.05 was considered
significant.
Results
Silencing of p53 mutants in bladder cancer cells
First, we checked the effects of the p53-targeting siRNA
(siP53) on the expression of endogenous mutant p53 in
5637 and T24 human bladder cancer cell lines, which had
been transfected with 50 nmol/l siP53 or a control dsRNA
(siCon). At 48 hours after transfection, expression of p53
mRNA and protein was assessed by real-time quantitative
PCR and western blotting respectively. Compared with
the mock and siCon transfections, siP53 caused a reduc-
tion of more than 70% reduction in expression of the mu-
tant p53 (Figure 1).
Knockdown of mutant p53 inhibits the growth and
viability of 5637 and T24 cells
We next investigated the effects of knockdown of mu-
tant p53 on bladder cancer cells. The two dsRNAs,
siP53 and siCon, were respectively transfected into 5637
and T24 cells at a concentration of 50 nmol/l. Phase-
contrast images of cells from the same fields were taken
48 hours after transfection. Morphologically, the mock
and siCon transfected cells maintained healthy growth,
whereas the cells transfected with siP53 lost viability,
and there was an evident decrease in cell number
(Figure 2).
Following this, the effects of siP53 at varying concen-
trations and times (24 to 72 hours) on the proliferation
and viability of 5637 and T24 cells were determined by
the MTT assay. Inhibition of cell growth and viability by
siP53 was dependent on dose and time (Figure 3). Re-
duction in 5637 cell viability with siP53 treatment at
concentrations of 5 to 100 nmol/l after 72 hours ranged
from 22.7% to 53.8%, whereas reduction of cell viability
in T24 cells ranged from 29.4% to 60.3% (Figure 3).
Silencing of mutant p53 induces G2-phase cell cycle
arrest in bladder cancer cells
In addition to their ability to interfere with wild-type
p53-mediated cell cycle arrest, many mutant p53 pro-
teins can actively promote cell growth by affecting vari-
ous proliferation-related genes [20,21]. Therefore, we
Figure 1 A p53-targeting small interfering (si)RNA (siP53) reduced p53 expression in T24 and 5637 human bladder cancer cells. p53
mRNA expression in (A) 5637 and (C) T24 cells transfected by siP53 or siCon were assessed by real-time quantitative PCR. The results were
normalized to GAPDH and are presented as the mean ± SD of three independent experiments. * P < 0.05 versus mock and small interfering
control (siCon) groups. The p53 protein levels in (B) 5637 and (D) T24 cells were assessed by western blotting analysis. β-actin levels were also
assessed and served as a loading control. A representative blot is shown from three independent experiments with identical results.
Zhu et al. World Journal of Surgical Oncology 2013, 11:22 Page 4 of 11
http://www.wjso.com/content/11/1/22assessed whether siP53-induced inhibition of growth
and viability is mediated via alterations in cell cycle
regulation. The supernatant including suspended cells
was removed and adherent live cells were harvested
after 48 hours of treatment. G2 phase arrest was seen inFigure 2 The p53-targeting small interfering (si)RNA (siP53) inhibited
50 nmol/l siP53, 50 nmol/l siCon or mock RNA. Cell images were taken at 4
cells were less dense and had more dead cells in the culture than the cellscells treated with 50 nmol/l siP53 (Figure 4). The G2-
phase population of the siP53-treated 5637 cells was
32.39% at 48 hours after treatment, and increased by
about 20% compared with controls, whereas the per-
centage of G2-phase T24 cells increased about 23% afterthe growth of cells. (A) 5637 and (B) T24 cells were transfected with
8 hours after transfection at 100× magnification. The siP53-transfected
in the siCon and mock groups.
Figure 3 The small interfering (si)P53 inhibited the viability of cells in a dose-dependent and time-dependent manner, as assessed by
the (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. For both (A) 5637 and (B) T24 cells, reduced cell viability
was seen after siP53 treatment (5 to 100 nmol/l) at 24, 48, and 72 hours. Data are presented as means ± SD (n = 8).
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in the G2 phase was found to be associated with a con-
comitant significant decrease in the S-phase population.
Next, we examined the expression of several cell
cycle-related proteins. Interference with the cell cycle in
5637 cells was associated with decreased expression of
cyclin B1 and cyclin A, and reduced phosphorylation of
CDK1, but no alteration in the expression of other
cyclins and CDKs (Figure 5). The results of T24 cells
are similar (data not sown).Silencing of mutant p53 induces cell apoptosis in bladder
cancer cells
We next investigated the relationship between siP53-
mediated loss of cell viability and apoptosis by flow-
cytometry analysis of 5637 cells labeled with PI and
annexin V. We found that after 72 hours of treatment,
siP53 caused evident apoptosis in 5637 cells. The num-
ber of early apoptotic cells (LR quadrant) increased to
6.2% in 5637 cells, and the number of late apoptotic cells
(UR quadrant) increased to 17.9% (Figure 6A). These
Figure 4 Treatment with 50 nmol/l small interfering (si)P53 induced G2-phase cell cycle arrest in human bladder cancer cells detected
by flow cytometry. (A) 5637 and (B) T24 cells. The sub-G0/G1 cells were not included in the calculations. A representative image is shown from
three independent experiments with identical results, and these data are the average results of three independent experiments.
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cell necrosis, which might be a secondary event in the
apoptotic process. Similar results were also seen in T24
cells (data not shown).
Accordingly, activation of caspase 9 and caspase 3 and
cleavage of PARP, which represent one of the final steps
of the proteolytic caspase cascade and reliably indicate
ongoing apoptosis, were present in siP53-treated 5637
cells (Figure 6B).
Silencing of mutant p53 cooperates with cisplatin in
producing inhibition of bladder cancer cells
Cisplatin is the main chemotherapy drug for advanced
bladder cancer. As explained in the Introduction, there
have been conflicting findings as to whether p53 muta-
tions confer increased responsiveness or increased resist-
ance to cisplatin-based systemic chemotherapy in bladder
cancer [17]. Thus, we used MTT assay to determine the
combined effects of siP53 and cisplatin on 5637 bladder
cancer cells.
After transfection with mock, siCon, or siP53 siRNAs
for 24 hours, cells were sub-divided into two groups,
and treated or not with 1 μg/ml cisplatin for another 48
hours. The average reduction in cell viability with siP53
+ cispaltin treatment was 72.3% (Figure 7), which wasmuch greater than the reduction obtained with the sin-
gle treatment of siP53 (38.7%) or cisplatin (44.9%). Simi-
lar results were also seen in T24 cells (data not shown).
Both the live cells and the supernatant were then har-
vested to assess the effects of the treatment above by
flow cytometry. Compared with the siCon-treated group,
G2-phase arrest was seen in both the siP53-treated and
cisplatin-treated groups (Figure 8). Moreover, there was
a significant increase in the sub-G0/G1 population in
these two groups (28.32% and 19.74%, respectively), indi-
cating apoptotic cells. When siP53-transfected cells were
subsequently treated with cisplatin for 48 hours, the pro-
portion of sub-G0/G1 cells increased to 51.51%, suggest-
ing that the p53-targeting siRNA can co-operate with
cisplatin in the inhibition of bladder cancer cells.
Discussion
Mutations in the TP53 gene, encoding the p53 tumor
suppressor, are arguably the most common type of gene-
specific alterations in human cancer. This emphasizes
the pivotal role of p53 as a major mainstay of the body’s
built-in anticancer defense mechanisms. As the field of
p53 research evolves, it is increasingly evident that many
p53 mutants not only lose their own tumor-suppressive
functions and acquire dominant-negative activities over
Figure 5 The effects of small interfering (si)P53 on cell
cycle-related proteins in 5637 cells. Cell lysates were analyzed by
immunoblotting. A representative blot is shown from three
independent experiments with identical results.
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genic properties that are not present in wild-type p53;
this phenomenon is termed the ‘gain-of-function hy-
pothesis’. For instance, overexpression of p53 mutants in
cultured cells was shown to interfere with apoptosis, en-
hance proliferation, and increase resistance of the cells
to chemotherapy [22-24]. Moreover, transfection of
mutant p53 into TP53-null cells was shown to enhance
their ability to form tumors in mice [25]. Therefore,
whereas wild-type p53 is a potent tumor suppressor,
cancer-associated p53 mutants possess the attributes of
oncogenes, suggesting that knockdown of mutant p53 may
restrain or reverse the process of oncogenesis.
Recently, therapeutics based on RNA interference
(RNAi) have become powerful and useful methods for
the treatment of many diseases, including cancer, be-
cause of the high specificity, high efficacy and low tox-
icity of the RNAi trigger, small dsRNA [26,27]. Stable or
conditional knockdown of endogenous mutant p53 by
siRNAs in various human cancer cell lines, such as lung,
breast, and colon cancer cells, has been reported toreduce their growth rate and chemoresistance in vitro,
and their ability to form tumors in nude mice [13,14,28].
A recent study also obtained consistent results showing
that siRNA targeting mutant p53 could induce cell cycle
arrest and apoptosis in human prostate cancer cells [29].
In the current study, we used siRNAs that targeted p53
mutants to transfect human bladder cancer cell lines
expressing only p53 mutants endogenously, and found
that the transfection resulted in suppressed cell growth
and viability via induction of cell cycle arrest and apop-
totic cell death.
In numerous cancer types, mutations in TP53 are
strongly associated with high expression levels of the
proliferation-associated gene cluster, comprised mainly
of the genes that participate in the core processes of the
cell cycle [30]. Moreover, several p53 mutants were re-
cently shown to repress wild-type p53 target genes,
which encode pivotal cell cycle inhibitors (such as p21
and GADD45α (growth arrest and DNA-damage-
inducible 45α)), leading to alteration of cyclins/CDKs
and an increased proliferation rate [31]. Whereas over-
coming the G2/M checkpoint to initiate mitosis requires
cyclin B/CDK1 to be activated, cyclin A seems to be
required for both S-phase and M-phase [32]. Cyclin A/
CDK2 drives G2-phase cells into mitosis, and is a rate-
limiting component required for entry into mitosis [33].
Our analysis of cell cycle-related proteins showed that in
the siP53-treated cells, there was significantly decreased
expression of both cyclin B1 and cyclin A and reduced
phosphorylation of CDK1, supporting the induction of G2
phase arrest detected by flow cytometry. Meanwhile, our
study also showed activation of caspase-9 and caspase-3
and proteolytic cleavage of PARP in these cells, which play
central roles during cell apoptosis [34,35].
Over the past two decades, cisplatin-based combin-
ation chemotherapy regimens, such as CMV (cisplatin,
methotrexate, and vinblastin) or M-VAC (methotrexate,
vinblastin, doxorubicin, and cisplatin) have been mainly
used for patients with advanced bladder cancer [36-39].
However, because of their severe systemic toxicity and the
poor overall prognosis of patients, novel therapeutic
schemes containing different drug cocktails have been
developed, with cisplatin occupying a central position in
theseregimen (for example the GC (gemcitabine + cis-
platin) regimen) [40]. It is generally accepted that DNA is
the preferential and cytotoxic target for cisplatin [41-43].
Cisplatin-mediated damage of genomic DNA causes se-
vere cell cycle perturbation and arrest at certain check-
points, and in the absence of adequate repair, the affected
cells undergo cell apoptosis. There has been controversy
about the influence of mutant p53 on the responsiveness
to the cisplatin-based systemic chemotherapy in bladder
cancer [17]. Several studies have reported that patients
with p53-altered bladder cancer benefited from adjuvant
Figure 6 Small interfering (si)P53-induced apoptosis in 5637 human bladder cancer cells. (A) siP53 treatment resulted in apoptosis in 5637
cells detected by flow cytometry using a double-staining method with fluorescein thiocyanate-conjugated annexin V and propidium iodide.
(B) siP53 treatment activated caspase-3, caspase-9, and poly(ADP-ribose) polymerase (PARP) in 5637 cells. Representative images and blots from
three independent experiments with identical results are shown, and these data are the average results of three independent experiments.
Figure 7 Silencing of mutant p53 cooperates with cisplatin in inhibiting the viability and growth of 5637 cells assessed by the
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. These data are presented as means ± SD (n = 8). * P < 0.05
versus single treatment with the conrol (siCon) or mock DNA. ** P < 0.05 versus single treatment with siP53 + cisplatin.
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Figure 8 Silencing of mutant p53 cooperates with cisplatin in inducing apoptosis in 5637 cells assessed by flow cytometry. The
percentage of cells in G1, S, or G2 phase equals the number of cells in each phase divided by the number in all three phases, and the
percentage of sub-G0/G1 cells equals the number of sub-G0/G1 cells divided by the number of all cells counted. A representative image is
shown from three independent experiments with identical results, and these data are the average results of three independent experiments.
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a poor response to systemic cisplatin-based chemotherapy
[45], which might be related to the protection of cells from
DNA damage by wild-type p53. However, other studies
showed that mutations in TP53 were associated with drug
resistance in several malignancies and cell lines [22,46],
which might be partially attributable to transcriptional ac-
tivation of the multi-drug resistance 1 (MDR1) gene
[47,48] and interference with apoptosis [23] by mutant
p53. Therefore, targeting mutant p53 may sensitize the
cancer cells to chemotherapy in at least some bladder can-
cers. In the current study, we found that knockdown of
mutant p53 by siRNA in 5637 and T24 bladder cancercells could co-operate with cisplatin and enhance its antic-
ancer effects additively via increased cell apoptosis.
Conclusions
Our study indicated that knockdown of mutant p53 by
siRNA was able to induce G2-phase cell cycle arrest and
apoptosis in 5637 and T24 human bladder cancer cells.
Moreover, this strategy cooperated with cisplatin in the
inhibition of bladder cancer cells. Our results provide
evidence that targeting mutant p53 by RNAi may serve
as a promising therapeutic strategy for the treatment of
partial advanced bladder cancer bearing p53 mutations.
Despite the promise, the principal challenges that
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therapeutics are the hurdles of delivery and target valid-
ation in vivo. Further studies are needed to delineate the
exact mechanism and verify in vivo effectiveness for clin-
ical use in the future.
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